Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue

Vahid Heravi Shargh; Jeni Luckett; Kaouthar Bouzinab; Stephen Paisey; Lyudmila Turyanska; William G. B. Singleton; Stephen Lowis; Pavel Gershkovich; Tracey D. Bradshaw; Malcolm F. G. Stevens; Alison Bienemann; Beth Coyle

doi:10.1021/acsami.1c04164

journal article·2021-08-04Open access

Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue

Vahid Heravi Shargh, Jeni Luckett, Kaouthar Bouzinab, Stephen Paisey, Lyudmila Turyanska, William G. B. Singleton, Stephen Lowis, Pavel Gershkovich, Tracey D. Bradshaw, Malcolm F. G. Stevens, Alison Bienemann, Beth Coyle

ACS Applied Materials & Interfaces· Volume 13· Issue 30

Publisher page Open full text

Source abstract

Abstract

Zr radionuclide in terms of localized distribution kinetics and retention within the brain parenchyma. Overall, both NP formulations of N3P represent promising approaches for treatment of TMZ-resistant DIPG and merit the next phase of preclinical evaluation.

Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Glioma Diagnosis and Treatment · Nanoparticle-Based Drug Delivery · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Wales Research and Diagnostic PET Imaging Centre, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom

Faculty of Engineering, University of Nottingham, Nottingham, Nottinghamshire NG7 2RD, United Kingdom

Translational Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, BS8 1TD, United Kingdom

Funding

Research Councils UK · CHILDREN with CANCER UK

References (66)

Show source-provided references

1. 10.1007/s11060-020-03553-110.1007/s11060-020-03553-1 ↗

2. 10.1016/j.critrevonc.2017.10.01310.1016/j.critrevonc.2017.10.013 ↗

3. 10.3389/fonc.2019.0156810.3389/fonc.2019.01568 ↗

4. 10.1158/1078-0432.CCR-19-200010.1158/1078-0432.CCR-19-2000 ↗

5. 10.1159/00036613110.1159/000366131 ↗

6. 10.1039/C6MD00384B10.1039/C6MD00384B ↗

7. 10.20517/cdr.2019.6410.20517/cdr.2019.64 ↗

8. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗

9. 10.1016/j.canlet.2015.07.01310.1016/j.canlet.2015.07.013 ↗

10. 10.1016/j.neo.2018.05.00110.1016/j.neo.2018.05.001 ↗

11. 10.1215/15228517-2-1-4510.1215/15228517-2-1-45 ↗

12. 10.1007/s11060-007-9403-610.1007/s11060-007-9403-6 ↗

13. 10.1517/1474033090291828110.1517/14740330902918281 ↗

14. 10.3389/fonc.2019.0096610.3389/fonc.2019.00966 ↗

15. 10.1007/s11060-010-0272-z10.1007/s11060-010-0272-z ↗

16. 10.1016/j.biomaterials.2009.01.00310.1016/j.biomaterials.2009.01.003 ↗

17. 10.3389/fonc.2017.0025410.3389/fonc.2017.00254 ↗

18. 10.1016/j.jconrel.2020.11.02210.1016/j.jconrel.2020.11.022 ↗

19. 10.1002/adtp.20200012410.1002/adtp.202000124 ↗

20. 10.1371/journal.pone.013226610.1371/journal.pone.0132266 ↗

21. 10.2147/IJN.S12530010.2147/IJN.S125300 ↗

22. 10.1080/17425247.2017.124352810.1080/17425247.2017.1243528 ↗

23. 10.1039/C5BM00067J10.1039/C5BM00067J ↗

24. 10.1039/c0jm04321d10.1039/c0jm04321d ↗

25. 10.1007/s13346-020-00778-510.1007/s13346-020-00778-5 ↗

26. 10.3390/molecules2407138710.3390/molecules24071387 ↗

27. 10.3390/ijms2112440810.3390/ijms21124408 ↗

28. 10.1002/jps.2249610.1002/jps.22496 ↗

29. 10.1016/j.ijpharm.2017.10.01410.1016/j.ijpharm.2017.10.014 ↗

30. 10.1021/acsami.0c0151410.1021/acsami.0c01514 ↗

31. 10.1016/j.ijpharm.2016.10.05710.1016/j.ijpharm.2016.10.057 ↗

32. 10.3109/08982104.2016.114018410.3109/08982104.2016.1140184 ↗

33. 10.1080/10717544.2018.146408210.1080/10717544.2018.1464082 ↗

34. 10.3389/fimmu.2019.0132110.3389/fimmu.2019.01321 ↗

35. 10.1016/0003-2697(76)90527-310.1016/0003-2697(76)90527-3 ↗

36. 10.1021/acsami.9b1484910.1021/acsami.9b14849 ↗

37. 10.1002/cnr2.115510.1002/cnr2.1155 ↗

38. 10.1016/j.jconrel.2017.06.02810.1016/j.jconrel.2017.06.028 ↗

39. 10.1021/bi962148u10.1021/bi962148u ↗

40. 10.1016/j.supflu.2020.10498410.1016/j.supflu.2020.104984 ↗

41. 10.1517/17425247.5.9.100310.1517/17425247.5.9.1003 ↗

42. 10.1146/annurev.bb.09.060180.00234310.1146/annurev.bb.09.060180.002343 ↗

43. 10.1016/j.brainres.2004.12.00710.1016/j.brainres.2004.12.007 ↗

44. 10.1073/pnas.130450411010.1073/pnas.1304504110 ↗

45. 10.1126/scitranslmed.300359410.1126/scitranslmed.3003594 ↗

46. 10.1016/j.biomaterials.2018.06.02410.1016/j.biomaterials.2018.06.024 ↗

47. 10.1158/0008-5472.CAN-05-353510.1158/0008-5472.CAN-05-3535 ↗

48. 10.1215/15228517-2006-00110.1215/15228517-2006-001 ↗

49. 10.1021/bm200026v10.1021/bm200026v ↗

50. 10.1002/adhm.20150038910.1002/adhm.201500389 ↗

51. 10.1021/la403142710.1021/la4031427 ↗

52. 10.1007/s11095-017-2097-310.1007/s11095-017-2097-3 ↗

53. 10.1021/acs.bioconjchem.6b0060610.1021/acs.bioconjchem.6b00606 ↗

54. 10.1021/acsami.9b1382910.1021/acsami.9b13829 ↗

55. 10.1021/am509216510.1021/am5092165 ↗

56. 10.1038/s41598-017-06888-410.1038/s41598-017-06888-4 ↗

57. 10.1039/c2cc35131e10.1039/c2cc35131e ↗

58. 10.1021/acschemneuro.8b0033910.1021/acschemneuro.8b00339 ↗

59. 10.2217/nnm.15.19510.2217/nnm.15.195 ↗

60. 10.1186/s12935-019-0733-110.1186/s12935-019-0733-1 ↗

61. 10.18632/oncotarget.993510.18632/oncotarget.9935 ↗

62. 10.3892/or.2015.376710.3892/or.2015.3767 ↗

63. 10.1002/bit.2684510.1002/bit.26845 ↗

64. Shen Y. · Am. J. Cancer Res. · 2018 · 8 · 916

65. 10.1021/bc500315j10.1021/bc500315j ↗

66. 10.3171/2018.2.PEDS1766310.3171/2018.2.PEDS17663 ↗